Is fast-acting insulin aspart (Fiasp) approved for use with the OmniPod 5 insulin pump?

Fiasp Approval Status with OmniPod 5

Fiasp (fast-acting insulin aspart) is FDA-approved for use in insulin pumps generally, but you must verify compatibility with the specific OmniPod 5 system by consulting the pump's user manual, as the FDA label explicitly requires checking pump compatibility before use.

Key FDA Label Requirements

The Fiasp prescribing information states: "Refer to the continuous subcutaneous insulin infusion pump user manual to see if FIASP or FIASP PumpCart can be used with the insulin pump" 1. This is a critical directive that places the responsibility on both prescriber and patient to confirm device-specific compatibility.

What This Means Clinically

• FDA approval exists for Fiasp in continuous subcutaneous insulin infusion (CSII) systems broadly 1
• Device-specific approval requires verification with the OmniPod 5 manufacturer's documentation
• The FDA label does not provide a list of compatible pumps—this information must come from Insulet (OmniPod manufacturer) or the pump's instructions for use

Practical Considerations for Pump Use

If OmniPod 5 compatibility is confirmed, the following Fiasp-specific requirements apply:

Reservoir Management

• Change FIASP in pump reservoir at least every 6 days 1
• For PumpCart cartridges: replace at least every 4 days 1
• Follow whichever timeframe is shorter between Fiasp requirements and pump manual instructions 1
• Do not expose Fiasp in the pump reservoir to temperatures >37°C (98.6°F) 1

Critical Safety Points

• Do not mix Fiasp with any other insulin in the pump 1
• Rotate infusion sites within the same region to reduce lipodystrophy risk 1
• Train patients to have alternate insulin therapy available for pump failure 1
• Closely monitor blood glucose when converting insulins in pumps, as individualization of pump parameters may be necessary 1

Evidence from Clinical Practice

Research demonstrates Fiasp can be used effectively in insulin pumps when properly managed:

• A 6-week compatibility study showed no microscopically confirmed infusion-set occlusions with Fiasp in MiniMed pumps 2
• The onset 5 trial confirmed non-inferiority of Fiasp versus insulin aspart in CSII therapy, with superior postprandial glucose control 3
• Clinical experience indicates all pump settings should be reviewed when initiating Fiasp with CSII 3

Common Pitfall

Premature infusion-set changes were more common with Fiasp (44%) versus standard insulin aspart (16.7%) in one study 2, though this did not represent true occlusions. This suggests patients may need education about distinguishing true pump malfunction from normal operation.

Action Steps

1. Contact Insulet or check OmniPod 5 user manual to confirm Fiasp is listed as a compatible insulin
2. If compatible, ensure patient understands the 6-day maximum reservoir time (shorter than some other insulins)
3. Review and potentially adjust all pump settings (basal rates, insulin-to-carb ratios, correction factors) when switching to Fiasp 3, 4
4. Consider using continuous glucose monitoring to optimize settings during the transition 3
5. Educate patient on backup insulin administration methods 1

The FDA has approved Fiasp for pump use, but device-specific compatibility must be independently verified before prescribing for the OmniPod 5 system 1.